GSK has lifted its full-year profit forecast after the world’s first jab for the respiratory syncytial virus (RSV) helped power a strong third quarter of vaccine sales at the UK drugmaker.
葛兰素史克(GSK)上调了全年利润预测，此前manbetx app苹果 首款呼吸道合胞病毒(RSV)疫苗帮助这家英国制药商在第三季度实现强劲的疫苗销售业绩。
您已阅读6%（254字），剩余94%（4050字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。